Vitamin K3 (Menadione) Targets TBK1 to Enhance the Efficacy of Pirfenidone in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis
- 1State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-Di Herbs, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
- 2Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China
- 3Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang 330115, China
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible interstitial lung disease. Current antifibrotic drugs, exemplified by pirfenidone (PFD), only slow disease progression with limited efficacy and adverse effects, underscoring the need for novel therapeutic strategies. By integrating single-cell transcriptomics with the Drug2Cell algorithm, we performed drug prioritization at single-cell resolution and identified menadione (vitamin K3, VK3), a synthetic naphthoquinone and the minimal core of naturally occurring vitamin K, as a candidate preferentially active in alveolar epithelial cells. In bleomycin (BLM)-stimulated A549 cells and a mouse model of pulmonary fibrosis, therapeutic co-administration of low-dose VK3 and PFD reduced vimentin expression by 44.8% and collagen deposition by 50.3%, and decreased fibroblast abundance by 36.7%, thereby attenuating histopathological damage and restoring BLM-disrupted alveolar epithelial homeostasis. Experiments with VK3 alone further demonstrated that its antifibrotic activity is independent of conversion to vitamin K2. Mechanistically, thermal proteome profiling identified TANK-binding kinase 1 (TBK1) as the principal candidate target; molecular docking and molecular dynamics simulations predicted a stable binding mode, independently confirmed by biolayer interferometry and differential scanning fluorimetry, demonstrating direct binding of VK3 to TBK1 with nanomolar affinity. TBK1 knockdown suppressed BLM-induced fibrotic responses, establishing TBK1 as a positive regulator of pulmonary fibrosis. In vitro signaling analysis revealed that VK3 plus PFD inhibits phosphorylation of TBK1 and STAT3, whereas PFD alone reduces phosphorylation of JAK1 and STAT3, suggesting that both agents converge on STAT3 through distinct upstream nodes. Although VK3 exhibits dose-dependent cytotoxicity precluding direct clinical use as monotherapy, its validated high-affinity target TBK1 and privileged naphthoquinone scaffold lay a rational foundation for lead optimization toward safer anti-IPF agents, and its ability to enhance PFD efficacy supports further development as an adjunct to existing antifibrotic therapy.
Related
- A Balanced Chromosomal Rearrangement Disrupting the Telomerase RNA Component Gene Causes Short Telomere-Mediated Pulmonary Fibrosis
- Mechanosignaling Promotes Macrophage Apoptosis Resistance in Pulmonary Fibrosis via Metabolic Reprogramming
- Pulmonary Fibroblast Heterogeneity and Functional Remodeling in Idiopathic Pulmonary Fibrosis: State Persistence and Reversibility
- Single-Cell Transcriptomic Analysis Identifies a Translation/RBP-Related Fibroblast Signature for Drug Repurposing in Idiopathic Pulmonary Fibrosis
- Emerging Therapies in Pulmonary Fibrosis: A Common Pathway for the Action of Diverse Pharmacologic Agents
BibTeX
@article{wang2026vitamin,
title = {{Vitamin K3 (Menadione) Targets TBK1 to Enhance the Efficacy of Pirfenidone in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis}},
author = {Yanan Wang and Junxian Cao and Yingxin Zhou and Xuxia Cao and Shiwen Deng and Yu Li and Caifeng Li and Shihuan Tang and Peng Chen},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219739},
url = {https://www.mdpi.com/1422-0067/27/21/9739},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Vitamin K3 (Menadione) Targets TBK1 to Enhance the Efficacy of Pirfenidone in a Mouse Model of Bleomycin-Induced Pulmonary Fibrosis
AU - Yanan Wang
AU - Junxian Cao
AU - Yingxin Zhou
AU - Xuxia Cao
AU - Shiwen Deng
AU - Yu Li
AU - Caifeng Li
AU - Shihuan Tang
AU - Peng Chen
PY - 2026
DA - 2026/10/30
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219739
UR - https://www.mdpi.com/1422-0067/27/21/9739
AB - Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible interstitial lung disease. Current antifibrotic drugs, exemplified by pirfenidone (PFD), only slow disease progression with limited efficacy and adverse effects, underscoring the need for novel therapeutic strategies. By integrating single-cell transcriptomics with the Drug2Cell algorithm, we performed drug prioritization at single-cell resolution and identified menadione (vitamin K3, VK3), a synthetic naphthoquinone and the minimal core of naturally occurring vitamin K, as a candidate preferentially active in alveolar epithelial cells. In bleomycin (BLM)-stimulated A549 cells and a mouse model of pulmonary fibrosis, therapeutic co-administration of low-dose VK3 and PFD reduced vimentin expression by 44.8% and collagen deposition by 50.3%, and decreased fibroblast abundance by 36.7%, thereby attenuating histopathological damage and restoring BLM-disrupted alveolar epithelial homeostasis. Experiments with VK3 alone further demonstrated that its antifibrotic activity is independent of conversion to vitamin K2. Mechanistically, thermal proteome profiling identified TANK-binding kinase 1 (TBK1) as the principal candidate target; molecular docking and molecular dynamics simulations predicted a stable binding mode, independently confirmed by biolayer interferometry and differential scanning fluorimetry, demonstrating direct binding of VK3 to TBK1 with nanomolar affinity. TBK1 knockdown suppressed BLM-induced fibrotic responses, establishing TBK1 as a positive regulator of pulmonary fibrosis. In vitro signaling analysis revealed that VK3 plus PFD inhibits phosphorylation of TBK1 and STAT3, whereas PFD alone reduces phosphorylation of JAK1 and STAT3, suggesting that both agents converge on STAT3 through distinct upstream nodes. Although VK3 exhibits dose-dependent cytotoxicity precluding direct clinical use as monotherapy, its validated high-affinity target TBK1 and privileged naphthoquinone scaffold lay a rational foundation for lead optimization toward safer anti-IPF agents, and its ability to enhance PFD efficacy supports further development as an adjunct to existing antifibrotic therapy.
SN - 1422-0067
ER -